Dr. Reddy’s Laboratories Ltd ADR (RDY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $12.29B
Last updated: Nov 17, 2026 at 4:37 PM ET
Dr. Reddy’s Laboratories Ltd ADR (RDY) Statistics
Dr. Reddy’s Laboratories Ltd ADR (RDY) has a market cap of $12.29B. Its return on invested capital of 5.72% compares with a 11.58% median across 9 similar companies.
Total Valuation
| Market Cap | $12.29B |
|---|---|
| Latest price (Nov 17, 2026) | $14.80 |
Key Dates
The last ex-dividend date was Jul 24, 2026.
| Last Earnings Date | Oct 23, 2026 |
|---|---|
| Last Ex-Dividend Date | Jul 24, 2026 |
| Last Payment Date | Aug 5, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 3.5x and 3.1x.
| P/E Ratio | 39.8x |
|---|---|
| P/S Ratio | 3.5x |
| P/B Ratio | 3.1x |
| P/TBV Ratio | 4.4x |
| P/FCF Ratio | 94.8x |
| PEG Ratio | 9.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 22.3x EBITDA and 99.5x free cash flow.
| EV / EBITDA | 22.3x |
|---|---|
| EV / FCF | 99.5x |
Price Statistics
The stock is up 6.92% over 52 weeks and trades 12.55% above its 50-day average.
| Beta (1Y) | 0.35 |
|---|---|
| 52-Week Change | +6.92% |
| 1-Month Change | +13.15% |
| 3-Month Change | +22.21% |
| 6-Month Change | +10.82% |
| 5-Year Change | +15.32% |
| 10-Year Change | +43.74% |
| Total Return (1Y) | +7.99% |
| Total Return (3Y CAGR) | +4.09% |
| Total Return (5Y CAGR) | +4.33% |
| Return vs SPY (1Y) | -5.25% |
| Max Drawdown (1Y) | -26.01% |
| Max Drawdown (3Y) | -32.01% |
| Sharpe Ratio (1Y) | 0.23 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $13.15 |
| 200-Day Average | $13.24 |
| 52-Week Range | $11.28 to $15.49 |
| RSI (14 Days) | 69.7 |
| Average Volume (20 Days) | 2.79M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.93x current liabilities, and total debt is 0.19x shareholder equity.
| Current Ratio | 1.93x |
|---|---|
| Quick Ratio | 1.40x |
| Debt / Equity | 0.19x |
| Debt / EBITDA | 1.30x |
| Interest Coverage | 7.23x |
Returns and Efficiency
Return on invested capital is 5.72% over the last 12 months, against a 5-year average of 13.94%.
| Return on Equity (ROE) | 7.47% |
|---|---|
| Return on Assets (ROA) | 5.02% |
| Return on Invested Capital (ROIC) | 5.72% |
| ROE (5Y Average) | 16.18% |
| ROA (5Y Average) | 11.17% |
| ROIC (5Y Average) | 13.94% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 2.11x |
| Receivables Turnover | 2.99x |
| Cash Conversion Cycle | 216 days |
Taxes
Income tax took 21.66% of pretax income over the last 12 months.
| Income Tax (TTM) | INR 7.64B |
|---|---|
| Effective Tax Rate | 21.66% |
Scores
RDY has an Altman Z-Score of 5.78, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.78 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of INR 331.38B over the last 12 months is down 3.15% from the 12 months before.
| Revenue | INR 331.38B |
|---|---|
| Revenue Growth (YoY) | -3.15% |
| Gross Profit | INR 163.93B |
| Operating Income | INR 29.56B |
| Pretax Income | INR 35.27B |
| Net Income | INR 28.03B |
| EBITDA | INR 53.96B |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 67.22% of the INR 577.00B in total assets.
| Working Capital | INR 143.71B |
|---|---|
| Shareholder Equity | INR 387.87B |
| Tangible Book Value | INR 270.21B |
| Total Assets | INR 577.00B |
| Total Liabilities | INR 185.92B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After INR 18.10B of capital spending, operating cash flow left INR 12.01B of free cash flow.
| Operating Cash Flow | INR 30.11B |
|---|---|
| Capital Expenditures | INR 18.10B |
| Free Cash Flow | INR 12.01B |
| Depreciation and Amortization | INR 21.51B |
| Dividends Paid | INR 6.83B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 8.92%, against a 5-year average of 19.43%.
| Gross Margin | 49.47% |
|---|---|
| Operating Margin | 8.92% |
| Pretax Margin | 10.64% |
| Net Margin | 8.46% |
| EBITDA Margin | 16.28% |
| FCF Margin | 3.63% |
| Gross Margin (5Y Average) | 55.93% |
| Operating Margin (5Y Average) | 19.43% |
| Net Margin (5Y Average) | 15.88% |
Growth
Revenue grew 12.86% a year over 3 years.
| Revenue Growth (3Y CAGR) | +12.86% |
|---|---|
| Revenue Growth (5Y CAGR) | +168.02% |
| FCF Growth (3Y CAGR) | -7.08% |
| FCF Growth (5Y CAGR) | +6.76% |
| Operating Income Growth (3Y CAGR) | -5.08% |
Dividends and Yields
RDY pays out 37.79% of earnings as dividends.
| Dividend Per Share (Annual) | $0.06 |
|---|---|
| Dividend Yield | 0.43% |
| Dividend Growth (3Y CAGR) | +5.74% |
| Dividend Growth (5Y CAGR) | +6.53% |
| Payout Ratio | 37.79% |
| FCF Payout Ratio | 54.81% |
| Earnings Yield | 2.51% |
| FCF Yield | 1.05% |
Stock Splits
The last split was a 5-for-1 forward split on Nov 5, 2024.
| Last Split Date | Nov 5, 2024 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 5:1 |
Peer Position
Against 10 similar companies, RDY has the 2nd highest P/E.
P/E RatioPeer median 18.2x
P/S RatioPeer median 2.7x
ROICPeer median 11.58%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.88%
Dividend YieldPeer median 0.00%
| P/E Ratio | 39.8x vs 18.2x median |
|---|---|
| P/S Ratio | 3.5x vs 2.7x median |
| ROIC | 5.72% vs 11.58% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -3.15% vs +8.88% median |
| Dividend Yield | 0.43% vs 0.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RDY
What is RDY's market cap?
Dr. Reddy’s Laboratories Ltd ADR has a market cap of $12.29B.
What is RDY's P/E ratio?
Dr. Reddy’s Laboratories Ltd ADR has a trailing P/E ratio of 39.8x.
How many shares of RDY are outstanding?
Dr. Reddy’s Laboratories Ltd ADR has 833.33M shares outstanding. The count is up 0.04% from a year earlier.
Does RDY pay a dividend?
Yes. Dr. Reddy’s Laboratories Ltd ADR pays $0.06 a share a year, a dividend yield of 0.43%.
RDY pages: Overview, Dividends, Charting, Financials, Statistics, Valuation, Competitors